Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit
Marco A. Mascarella(Jewish General Hospital), Umamaheswar Duvvuri(City University of New York), Dan P. Zandberg(University of Pittsburgh Medical Center), Daniel Clayburgh(Oregon Health & Science University), James G. Herman(UPMC Hillman Cancer Center), Mark Kubik(UPMC Hillman Cancer Center), Sonali Joyce(University of Pittsburgh), Malabika Sen(University of Pittsburgh Medical Center), Shaum Sridharan(University of Pittsburgh), Tolani F. Olonisakin(Pulmonary and Allergy Associates), Varun Vendra(University of Pittsburgh Medical Center), James Ohr(University of Pittsburgh), Melonie A. Nance(Anna Needs Neuroblastoma Answers), Robert L. Ferris(University of Pittsburgh), Jennifer R. Grandis(University of California, San Francisco), Purva Rumde(University of Pittsburgh), Seungwon Kim(UPMC Hillman Cancer Center), Moon J. Fenton(University of Tennessee Health Science Center)
Cited by 10
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Head and neck squamous cell carcinoma
|Nature Reviews Disease Primers|2020|4k
Inactivation of the DNA-Repair Gene<i>MGMT</i>and the Clinical Response of Gliomas to Alkylating Agents
|New England Journal of Medicine|2000|2.2k
Incidence and functional consequences of <i>hMLH1</i> promoter hypermethylation in colorectal carcinoma
|Proceedings of the National Academy of Sciences|1998|1.9k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k